Intas Pharma Warning Letter 28 July 2023 | Learning from USFDA Warning Letters | 2023 Warning Letter

USFDA issued warning letter to Intas Pharmaceuticals Sanand Facility in Gujrat with 5 observation details for inspection conducted in Nov-Dec 2022. Several Data integrity concerns were noted and other concerns related to OOS investigation, control on computerized systems and process validation were also identified. Your queries: USFDA Warning Letters Warning Letter 2023 Warning Letters About the Channel: The channel provides details of pharmaceutical guidelines, important updates on pharmaceuticals and other professional topics like interview preparation, personality development etc. Contact us at: [email protected]   / proftalks1680     / 13995930   Subscribe to our channel for more informative videos:    / @proftalks1680   #usfda #warningletters #pharmaceuticalcompanies